Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents

BACKGROUND: Prescribing nonsteroidal antiinflammatory drugs (NSAIDs) is challenging because physicians have to consider gastrointestinal (GI) and cardiovascular (CV) safety issues.OBJECTIVE: The purpose of the study was to determine appropriate NSAID treatment strategies based on different combinations of GI and CV risks.METHODS: The working party comprised a multidisciplinary international panel of 19 experts. Two hundred eighty-eight vignettes were evaluated for the appropriateness of each of six options: naproxen, non-naproxen nonselective NSAIDs, naproxen plus proton pump inhibitor (PPI)/misoprostol, non-naproxen nonselective NSAID plus PPI/misoprostol, cyclooxygenase-2 selective NSAID (coxib), or coxib plus PPI/misoprostol. Using a two-stage modified Delphi process, the panel anonymously ranked the appropriateness of each option from 1 (extremely inappropriate) to 9 (extremely appropriate). Vignettes were considered appropriate if ≥80% of all panelists' scores were 7–9 and inappropriate if ≥80% of all panelists' scores were 1–3.RESULTS: The panel rated nonselective NSAIDs as appropriate when the patient had average GI risk (<70 yr of age; no prior upper GI event; no corticosteroids, antithrombotic agents, anticoagulants). In patients with GI risk factors, cotherapy with a PPI/misoprostol was appropriate. Either a nonselective NSAID or a coxib was rated appropriate in patients with average CV risk; naproxen was preferred in patients with high CV risk. None of the options was considered appropriate in patients with multiple GI risk factors and high CV risk.CONCLUSIONS: The initial choice of an NSAID (naproxen vs. others) relates to a patient's CV risk, and the need for therapy to decrease GI complications (PPI/misoprostol or coxibs) is determined by severity and number of GI risk factors.

[1]  P. Tugwell,et al.  Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  V. Wong,et al.  Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial , 2007, The Lancet.

[3]  H. El‐Serag,et al.  Cyclooxygenase‐2 selectivity of non‐steroidal anti‐inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident , 2007, Alimentary pharmacology & therapeutics.

[4]  E. Antman,et al.  Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. , 2007, Circulation.

[5]  C. Cannon,et al.  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison , 2007, The Lancet.

[6]  R. Moore,et al.  Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice , 2006, BMC musculoskeletal disorders.

[7]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[8]  R. Hunt,et al.  Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  T. Schnitzer.  Update on guidelines for the treatment of chronic musculoskeletal pain , 2006, Clinical Rheumatology.

[10]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[11]  Á. Lanas,et al.  Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations , 2006, Gut.

[12]  F. Chan,et al.  Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors , 2006, The American Journal of Gastroenterology.

[13]  J. Hippisley-Cox,et al.  Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[14]  Colin Baigent,et al.  Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.

[15]  K. Chu,et al.  Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. , 2005, The American journal of medicine.

[16]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[17]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[18]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[19]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[20]  D. Symmons,et al.  The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review , 2004, BMJ : British Medical Journal.

[21]  V. Wong,et al.  Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. , 2004, Gastroenterology.

[22]  L. Laine,et al.  Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy , 2004, Alimentary pharmacology & therapeutics.

[23]  V. Wong,et al.  Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. , 2002, The New England journal of medicine.

[24]  P Tugwell,et al.  Prevention of NSAID-induced gastroduodenal ulcers. , 2002, The Cochrane database of systematic reviews.

[25]  C. Bombardier,et al.  Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. , 2002, Gastroenterology.

[26]  EUROPEAN FEDERATION OF INTERNAL MEDICINE (EFIM) , 2002 .

[27]  D. Graham,et al.  Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. , 2002, Archives of internal medicine.

[28]  S. Gabriel,et al.  Adverse gastrointestinal effects of NSAIDs: consequences and costs. , 2001, Best practice & research. Clinical gastroenterology.

[29]  F. Chan,et al.  Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. , 2001, The New England journal of medicine.

[30]  F. Hasson,et al.  Research guidelines for the Delphi survey technique. , 2000, Journal of advanced nursing.

[31]  Á. Lanas,et al.  Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. , 2000, The New England journal of medicine.

[32]  A. Barkun,et al.  Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. , 1999, The New England journal of medicine.

[33]  L. G. García Rodríguez,et al.  Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. , 1999, Epidemiology.

[34]  A. Barkun,et al.  Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs , 1998 .

[35]  J. Senior,et al.  Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs , 1995, Annals of Internal Medicine.

[36]  J. Hallas,et al.  Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. , 1995, Scandinavian journal of gastroenterology.

[37]  H. Jick,et al.  Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs , 1994, The Lancet.

[38]  S. Gabriel,et al.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. , 1991, Annals of internal medicine.

[39]  W A Ray,et al.  Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. , 1991, Annals of internal medicine.

[40]  R. Brook,et al.  Consensus methods: characteristics and guidelines for use. , 1984, American journal of public health.

[41]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[42]  M. Postma,et al.  Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs , 2007, Drugs & aging.

[43]  F. Hasson,et al.  Consulting the oracle: ten lessons from using the Delphi technique in nursing research. , 2006, Journal of advanced nursing.

[44]  C. Bombardier,et al.  An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. , 2006, The Journal of rheumatology.

[45]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[46]  L. Wilkins,et al.  National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994, Circulation.